BSX
BOSTON SCIENTIFIC CORP
NYSE · Healthcare · Medical - Devices · US
$43.34
−0.48%Sep 17, 2026, 14:29 UTC
Boston Scientific shares fell 2.02% to $43.03 in New York trading after an analyst downgraded the stock to Neutral and cut the price target to $50 from $57.
Source:Sep 16, 2026, 09:02 UTC
AGCO, Boston Scientific (BSX), and Bath & Body Works (BBWI) were added to the Zacks Rank #5 (Strong Sell) List on September 16, 2026.
Source:Sep 11, 2026, 13:58 UTC
Boston Scientific restored manufacturing and shipping after a cyberattack but warned it will likely miss its Q3 and full-year financial guidance.
Source:Sep 10, 2026, 23:01 UTC
Boston Scientific (BSX) shares fell 4.14% to close at $43.10 on the latest trading day.
Source:Sep 10, 2026, 15:31 UTC
Boston Scientific restored key operations after a cyberattack, with products moving through its distribution network at or above normal levels as it works to fulfill customer orders and reduce backlogs.
Source:Sep 10, 2026, 12:39 UTC
Boston Scientific is currently carrying out a major restructuring plan that is expected to bring certain financial benefits, according to an executive of the company.
Source:Sep 10, 2026, 12:38 UTC
Boston Scientific is reassessing its 2027 performance framework due to a cybersecurity incident and will disclose forward-looking information on its October conference call.
Source:Sep 8, 2026, 10:39 UTC
Boston Scientific disclosed a cybersecurity incident that disrupted manufacturing and order shipments globally, likely to materially impact its third-quarter and full-year 2026 results.
Sep 3, 2026, 23:59 UTC
The FDA posted three Class 2 recall records for Boston Scientific's LUX-Dx heart monitor server software due to a flaw that can delay atrial fibrillation alerts.
Source:Aug 26, 2026, 14:58 UTC
The U.S. Food and Drug Administration classified Boston Scientific's recall of its Enroute product as the most severe level.
Source:Aug 23, 2026, 08:32 UTC
Callan Family Office LLC acquired a new position of 52,745 shares in Boston Scientific Corporation during the second quarter, valued at approximately $2,251,000.
Source:Aug 20, 2026, 07:16 UTC
Aurora Investment Counsel disclosed a new position in Boston Scientific Corporation, purchasing 43,857 shares valued at approximately $1,872,000.
Source:Aug 19, 2026, 06:39 UTC
Boston Scientific's next-generation prostate hyperplasia treatment device Rezūm EVO received approval from China's National Medical Products Administration, making China the first market globally to approve the product, which will be locally produced at Boston Scientific's Shanghai Lingang plant for the Chinese market.
Source:Aug 19, 2026, 02:59 UTC
Boston Scientific's new-generation FARASTAR™ pulsed field ablation system for atrial fibrillation treatment, produced at its Shanghai Lingang plant, received approval from China's National Medical Products Administration.
Source:Aug 13, 2026, 07:36 UTC
B. Riley Wealth Advisors Inc. reduced its stake in Boston Scientific Corporation by 56.1% during the quarter, selling 10,822 shares and retaining 8,467 shares, as disclosed in its SEC filing.
Source:Jul 30, 2026, 08:02 UTC
Boston Scientific plans job cuts in Ireland.
Source:Jul 29, 2026, 10:30 UTC
Boston Scientific Corporation reported net sales of $5.442 billion for the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis compared to the prior year period.
Jul 27, 2026, 22:09 UTC
Boston Scientific's board approved a new company-wide restructuring plan aimed at cutting costs and positioning the company for future growth, with expected job cuts.
Source:Jul 23, 2026, 19:57 UTC
Boston Scientific recalled over 750,000 Faradrive Steerable Sheaths due to hemostatic valve damage risk, classified as a Class II recall by the FDA.
Source:Jun 8, 2026, 03:45 UTC
Boston Scientific entered into an accelerated share repurchase agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock.
Source: